ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in therapeutic resistance treatments, has announced its participation in two major investor conferences in April 2025.
The company will present at two events:
- Needham's 24th Annual Healthcare Conference - Company overview presentation scheduled for Monday, April 7, 2025, at 1:30 p.m. ET
- Stifel 2025 Virtual Targeted Oncology Forum - Fireside chat participation on Wednesday, April 9, 2025, at 2:00 p.m. ET
Both events will be webcasted and accessible through ORIC's investor relations website, with replays available for 90 days post-event.
ORIC Pharmaceuticals (Nasdaq: ORIC), un'azienda oncologica in fase clinica specializzata nei trattamenti per la resistenza terapeutica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nell'aprile 2025.
L'azienda presenterà a due eventi:
- 24a Conferenza Annuale sulla Salute di Needham - Presentazione aziendale programmata per lunedì 7 aprile 2025, alle 13:30 ET
- Forum Virtuale di Oncologia Mirata Stifel 2025 - Partecipazione a una chiacchierata informale mercoledì 9 aprile 2025, alle 14:00 ET
Entrambi gli eventi saranno trasmessi in streaming e accessibili attraverso il sito web delle relazioni con gli investitori di ORIC, con repliche disponibili per 90 giorni dopo l'evento.
ORIC Pharmaceuticals (Nasdaq: ORIC), una empresa oncológica en etapa clínica especializada en tratamientos de resistencia terapéutica, ha anunciado su participación en dos importantes conferencias para inversores en abril de 2025.
La empresa presentará en dos eventos:
- 24ª Conferencia Anual de Salud de Needham - Presentación de la empresa programada para el lunes 7 de abril de 2025, a la 1:30 p.m. ET
- Foro Virtual de Oncología Dirigida Stifel 2025 - Participación en una charla informal el miércoles 9 de abril de 2025, a las 2:00 p.m. ET
Ambos eventos se transmitirán en línea y serán accesibles a través del sitio web de relaciones con inversores de ORIC, con repeticiones disponibles durante 90 días después del evento.
ORIC Pharmaceuticals (Nasdaq: ORIC), 치료 저항 치료를 전문으로 하는 임상 단계의 종양학 회사가 2025년 4월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 두 행사에서 발표할 예정입니다:
- 니드햄 제24회 연례 건강 회의 - 2025년 4월 7일 월요일 오후 1시 30분 ET에 예정된 회사 개요 발표
- 스티펠 2025년 가상 표적 종양학 포럼 - 2025년 4월 9일 수요일 오후 2시 ET에 진행되는 파이어사이드 채팅 참여
두 행사 모두 웹캐스트로 진행되며 ORIC의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 이벤트 종료 후 90일 동안 재생이 가능합니다.
ORIC Pharmaceuticals (Nasdaq: ORIC), une entreprise d'oncologie en phase clinique spécialisée dans les traitements de résistance thérapeutique, a annoncé sa participation à deux grandes conférences pour investisseurs en avril 2025.
L'entreprise présentera lors de deux événements :
- 24ème Conférence Annuelle sur la Santé de Needham - Présentation de l'entreprise prévue pour le lundi 7 avril 2025, à 13h30 ET
- Forum Virtuel d'Oncologie Ciblée Stifel 2025 - Participation à une discussion informelle le mercredi 9 avril 2025, à 14h00 ET
Les deux événements seront diffusés en direct et accessibles via le site web des relations investisseurs d'ORIC, avec des rediffusions disponibles pendant 90 jours après l'événement.
ORIC Pharmaceuticals (Nasdaq: ORIC), ein klinisches Onkologieunternehmen, das sich auf Therapieresistenzbehandlungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im April 2025 angekündigt.
Das Unternehmen wird bei zwei Veranstaltungen präsentieren:
- 24. Jahrestagung für Gesundheitswesen von Needham - Unternehmenspräsentation geplant für Montag, den 7. April 2025, um 13:30 Uhr ET
- Stifel 2025 Virtuelles Zielgerichtetes Onkologie-Forum - Teilnahme an einem Fireside-Chat am Mittwoch, den 9. April 2025, um 14:00 Uhr ET
Beide Veranstaltungen werden live übertragen und über die Investor Relations-Website von ORIC zugänglich sein, mit Wiederholungen, die 90 Tage nach der Veranstaltung verfügbar sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:
- Needham's 24th Annual Healthcare Conference – Presenting a company overview on Monday, April 7, 2025, at 1:30 p.m. ET
- Stifel 2025 Virtual Targeted Oncology Forum – Participating in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. ET
Webcasts of the presentation and discussion will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
When is ORIC Pharmaceuticals presenting at Needham's Healthcare Conference in 2025?
What investor conferences is ORIC (NASDAQ: ORIC) attending in April 2025?
How long will ORIC Pharmaceuticals' conference webcasts be available for replay?
What time is ORIC's fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum?
Where can investors access ORIC Pharmaceuticals' conference presentations?
